AmCad BioMed Corporation (TPEX:4188)

AmCad BioMed Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	12.12	17.76	29.66	47.04	58.51	59.65
Short-Term Investments	354.72	343.95	252.61	280.78	312.54	331.47
Trading Asset Securities	15.03	4	5	3.02	-	4
Cash & Short-Term Investments	381.88	365.71	287.27	330.84	371.05	395.12
Cash Growth	-18.71%	27.30%	-13.17%	-10.84%	-6.09%	-12.66%
Accounts Receivable	12.08	20.66	11.35	4.51	5.78	2.76
Other Receivables	0.17	0.01	-	0.06	0.13	1.71
Receivables	12.25	20.66	11.35	4.57	5.91	4.47
Inventory	30	30.09	25.02	23.33	21.24	21.73
Prepaid Expenses	1.73	1.28	2.07	1.02	2.03	0.29
Other Current Assets	7.22	0.34	0.18	0.12	0.31	0.51
Total Current Assets	433.07	418.09	325.89	359.88	400.54	422.12
Property, Plant & Equipment	77.07	82.92	82.71	79.81	88.23	81
Long-Term Investments	65.6	125.68	28.06	28.74	34.47	52.44
Goodwill	31.18	31.18	31.18	31.18	31.18	31.18
Other Intangible Assets	30.45	35.15	42.5	50.54	58.62	66.76
Other Long-Term Assets	1.77	1.87	2.3	3.72	2.72	3.05
Total Assets	639.13	694.87	512.65	553.86	615.75	656.55
Accounts Payable	3.14	2.74	1.95	1.06	1.15	1.55
Current Portion of Leases	2.28	5.15	4.4	3.88	4.42	2.04
Current Unearned Revenue	0.52	0.51	2.05	2.67	5.45	32.63
Other Current Liabilities	20.37	16.75	16.02	19.75	15.11	11.5
Total Current Liabilities	26.31	25.14	24.42	27.36	26.13	47.71
Long-Term Leases	3.67	5.72	9.99	6.43	10.31	2.22
Long-Term Unearned Revenue	-	-	-	-	-	4.43
Other Long-Term Liabilities	0.32	0.29	0.29	0.29	0.28	7.08
Total Liabilities	30.3	31.16	34.7	34.08	36.72	61.44
Common Stock	633.33	633.33	532.56	532.21	532.21	532.21
Additional Paid-In Capital	141.99	141.52	8.02	95.74	94.92	94.38
Retained Earnings	-239.02	-199.32	-148.74	-192.06	-138.57	-117.86
Comprehensive Income & Other	-11.19	-6.88	-11.25	-11.32	-5.59	-11.02
Total Common Equity	525.11	568.65	380.58	424.58	482.98	497.7
Minority Interest	83.72	95.07	97.37	95.2	96.06	97.4
Shareholders' Equity	608.83	663.72	477.95	519.78	579.03	595.1
Total Liabilities & Equity	639.13	694.87	512.65	553.86	615.75	656.55
Total Debt	5.95	10.87	14.39	10.31	14.73	4.25
Net Cash (Debt)	375.92	354.84	272.88	320.53	356.32	390.87
Net Cash Growth	-17.84%	30.03%	-14.87%	-10.04%	-8.84%	-11.60%
Net Cash Per Share	5.93	6.15	5.13	6.02	6.70	7.35
Filing Date Shares Outstanding	63.33	63.33	53.26	53.22	53.22	53.22
Total Common Shares Outstanding	63.33	63.33	53.26	53.22	53.22	53.22
Working Capital	406.76	392.94	301.47	332.52	374.41	374.4
Book Value Per Share	8.29	8.98	7.15	7.98	9.07	9.35
Tangible Book Value	463.49	502.33	306.9	342.87	393.18	399.76
Tangible Book Value Per Share	7.32	7.93	5.76	6.44	7.39	7.51
Land	52.94	52.94	52.94	52.94	52.94	52.94
Buildings	8.14	8.14	8.14	8.14	8.14	8.14
Machinery	16.15	15.57	25.15	48.47	47.34	44.92
Leasehold Improvements	-	-	-	0.82	0.82	1.48

Source: S&P Global Market Intelligence. Standard template. Financial Sources.